Indivior Names New Director Following Shareholder Vote

Indivior Pharmaceuticals Inc. elected one new director and accepted the departure of another at its annual meeting of security holders held on May 15, 2026, according to an 8-K filed with the SEC the same day.

The filing discloses actions under Item 5.02 and Item 5.07. Item 5.07 covers the submission of matters to a vote of security holders at the annual meeting. Item 5.02 addresses the departure of directors or principal officers and the election of new ones.

The company did not name the specific individuals involved, cite a cause for the departure, or provide an effective date beyond the meeting date itself.

The board change affects the governance of Indivior, a pharmaceutical company whose sole director departure and replacement shifts the composition for a board that oversees a company with a market presence in addiction-treatment therapies. Public companies maintain boards typically sized between seven and 12 members; one seat turning over represents a roughly 8-14 percent change in board membership depending on total size.

The operational delta is straightforward: the prior board composition that existed before the annual meeting has been replaced by a new composition effective May 15, 2026. The company must now update its disclosures to reflect the current directors.

Standard SEC rules require a Form 8-K within four business days of the event, a deadline the company met by filing on the meeting date. The new director assumes full fiduciary duties immediately, while the departing director's obligations end on the same date.

Downstream consequences include the obligation to file an updated director biography and any committee assignments in the company's next proxy statement or Form 10-K. The departure may require the board to reassign committee roles to maintain compliance with Nasdaq or NYSE independence and audit-committee rules.

If the departing director held a committee chair, the company must fill that position within the exchange's permitted timelines or risk temporary noncompliance. Markets and proxy advisory firms will receive the new board roster for use in future governance ratings.

This filing constitutes the official record of board-level decisions taken at Indivior's 2026 annual meeting. The company has followed the standard practice of reporting both voting results and director changes on Form 8-K rather than waiting for the next quarterly report.